Nephropathy in Diabetes

The most common cause of end stage renal disease (ESRD) requiring dialysis is diabetes. Both environmental and genetic factors have been postulated as the risk factors of Diabetic Nephropathy (DN). Hyperglycemia-induced metabolic and hemodynamic pathways are recognized to be mediators of kidney injury. Multiple biochemical pathways have been postulated that explain how hyperglycemia causes tissue damage: Non-enzymatic glycation that generates advanced glycation end products, activation of protein kinase C, acceleration of the polyol pathway and oxidative stress. Three major histologic pathological changes occur in DN: Mesangial expansion, GBM thickening, and glomerular sclerosis. It now seems clear in targeting a therapeutic regimen to achieve blood glucose, blood pressure and proteunuric goals, dietary protein and salt restriction, weight reduction, aggressive lipid lowering, smoking cessation and exercise. Multiple intensive interventions reduce cardiovascular events as well as nephropathy by about half when compared with conventional multifactorial treatment.

[1]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[2]  T. Nicotera,et al.  Oxidative damage to DNA in diabetes mellitus , 1996, The Lancet.

[3]  L. Groop,et al.  Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. , 1994, JAMA.

[4]  M. Seldin,et al.  Mexican-American admixture mapping analyses for diabetic nephropathy in type 2 diabetes mellitus. , 2010, Seminars in nephrology.

[5]  G. Blohmé,et al.  The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  B. Kestenbaum,et al.  Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. , 2007, Journal of the American Society of Nephrology : JASN.

[7]  E. Lewis,et al.  Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  P. O'Malley,et al.  Meta-Analysis: The Effect of Statins on Albuminuria , 2006, Annals of Internal Medicine.

[9]  C. Mogensen,et al.  The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy , 1983, Diabetes.

[10]  S. Kawazu,et al.  The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. , 1994, Journal of diabetes and its complications.

[11]  S. Mauer,et al.  Structural-functional correlations of diabetic nephropathy. , 1994, Kidney international.

[12]  B. Satirapoj Review on pathophysiology and treatment of diabetic kidney disease. , 2010, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[13]  M. Cooper,et al.  Agents in development for the treatment of diabetic nephropathy , 2008, Expert opinion on emerging drugs.

[14]  L. Groop,et al.  Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria , 1996 .

[15]  E. Morales,et al.  Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  H. van Goor,et al.  Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. , 2007, Kidney international.

[17]  R. Trevisan,et al.  Genetic factors in the development of diabetic nephropathy. , 1995, The Journal of laboratory and clinical medicine.

[18]  Jai Radhakrishnan,et al.  Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[19]  H. Ha,et al.  Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. , 2003, Journal of the American Society of Nephrology : JASN.

[20]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[21]  H. Parving,et al.  Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. , 1992, Kidney international.

[22]  G. Wolf,et al.  Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. , 2008, Current diabetes reviews.

[23]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[24]  H. Parving,et al.  Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. , 2002, Kidney international.

[25]  C. Delcroix,et al.  Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. , 2005, Journal of the American Society of Nephrology : JASN.

[26]  R. Bain,et al.  Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  Kdoqi KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  H. Ha,et al.  Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. , 2008, Diabetes research and clinical practice.

[29]  G. Remuzzi,et al.  Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.

[30]  H. Parving,et al.  Beneficial impact of spironolactone in diabetic nephropathy. , 2005, Kidney international.

[31]  E. Ritz,et al.  Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.

[32]  H. Haller,et al.  Inhibition of protein kinase C in diabetic nephropathy--where do we stand? , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  D. Sutherland,et al.  Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. , 2006, Kidney international.

[34]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[35]  S. Adler,et al.  Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. , 2006, Kidney international.

[36]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[37]  G. Jerums,et al.  A low-sodium diet potentiates the effects of losartan in type 2 diabetes. , 2002, Diabetes care.

[38]  M. Province,et al.  Prevention of Hemodynamic and Vascular Albumin Filtration Changes in Diabetic Rats by Aldose Reductase Inhibitors , 1989, Diabetes.

[39]  P. Raskin,et al.  Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. , 1991, The New England journal of medicine.

[40]  H. Parving,et al.  Prevention of diabetic renal disease with special reference to microalbuminuria , 1995, The Lancet.

[41]  G. Navis,et al.  Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. , 2008, Journal of the American Society of Nephrology : JASN.

[42]  H. Parving,et al.  Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes , 1988, British medical journal.

[43]  A. Krolewski,et al.  Familial factors determine the development of diabetic nephropathy in patients with IDDM , 1996, Diabetologia.

[44]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[45]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[46]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[47]  L. Groop,et al.  Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria , 1994 .

[48]  J. Mustonen,et al.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. , 2004, The New England journal of medicine.

[49]  Norman Fleischer,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .

[50]  R. Elston,et al.  Genome-Wide Scans for Diabetic Nephropathy and Albuminuria in Multiethnic Populations , 2007, Diabetes.

[51]  P. Rossing Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005 , 2005, Diabetologia.

[52]  H. Kobori,et al.  Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. , 2005, Journal of the American Society of Nephrology : JASN.

[53]  T. Meyer,et al.  Podocyte loss and progressive glomerular injury in type II diabetes. , 1997, The Journal of clinical investigation.

[54]  G. Bakris,et al.  Effects of Sodium Intake on Albumin Excretion in Patients with Diabetic Nephropathy Treated with Long-Acting Calcium Antagonists , 1996, Annals of Internal Medicine.

[55]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[56]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[57]  E. Ritz,et al.  Diabetic nephropathy in type II diabetes. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[58]  S. Bianchi,et al.  Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[59]  J. Ingelfinger,et al.  Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. , 2007, Kidney international.

[60]  T. Kern,et al.  High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. , 2005, Kidney international.

[61]  B. Brenner,et al.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.

[62]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[63]  S. Araki,et al.  Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. , 1995, Journal of diabetes and its complications.

[64]  B. Hoogwerf,et al.  Consensus Development Conference on the Diagnosis and Management of Nephropathy in Patients with Diabetes Mellitus , 1994, Diabetes Care.

[65]  N. Bank Mechanisms of diabetic hyperfiltration. , 1991, Kidney international.

[66]  C. Deerochanawong,et al.  Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[67]  Ashutosh Kumar Singh,et al.  Effect of glycated proteins on the matrix of glomerular epithelial cells. , 1998, Journal of the American Society of Nephrology : JASN.

[68]  S. Freytag,et al.  Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. , 1995, The Journal of clinical investigation.

[69]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.

[70]  H. Keen,et al.  RESTRICTION OF DIETARY PROTEIN AND PROGRESSION OF RENAL FAILURE IN DIABETIC NEPHROPATHY , 1989, The Lancet.

[71]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[72]  R. DeFronzo Diabetic nephropathy: Etiologic and therapeutic considerations , 1995 .

[73]  H. Parving Renoprotection in diabetes: genetic and non-genetic risk factors and treatment , 1998, Diabetologia.

[74]  R. Agarwal Effects of statins on renal function. , 2007, The American journal of cardiology.

[75]  H. Parving,et al.  Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. , 2005, Diabetes care.

[76]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[77]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[78]  H. Parving,et al.  Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. , 2003, Kidney international.

[79]  T. Miyata,et al.  Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. , 1999, Journal of the American Society of Nephrology : JASN.

[80]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[81]  Don Poldermans,et al.  Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function , 2006, Journal of hypertension.